Autophagy activation can partially rescue proteasome dysfunction-mediated cardiac toxicity

Area of Science:

• Cellular biology
• Cardiovascular research
• Proteostasis and mitostasis

Background:

• The ubiquitin-proteasome pathway is vital for cell viability, particularly in cardiomyocytes.
• Proteasome inhibitors used in cancer therapy can cause cardiac failure.
• The specific effects of heart-targeted proteasome dysfunction remain unclear.

Purpose of the Study:

• To investigate the consequences of heart-targeted proteasome dysfunction in a model organism.
• To explore the potential of autophagy activation as a therapeutic strategy against proteasome inhibitor-induced cardiotoxicity.

Main Methods:

• Utilized a fly experimental model with heart-targeted proteasome knockdown.
• Assessed proteome instability, mitostasis, cardiac activity, systemic toxicity, and longevity.
• Investigated the rescue effects of autophagy activation via dietary restriction and pharmacological agents (Rapamycin, Metformin).

Main Results:

• Heart-targeted proteasome knockdown led to proteome instability, defective mitostasis, disrupted cardiac activity, systemic toxicity, and reduced longevity.
• Autophagy activation partially rescued these phenotypes.
• Rapamycin and Metformin administration mitigated cardiotoxicity and improved longevity in flies treated with proteasome inhibitors.

Conclusions:

• Heart-targeted proteasome dysfunction significantly impairs cardiac function and overall health.
• Autophagic inducers show promise as a novel intervention for managing proteasome inhibitor-induced cardiovascular complications.